Plain-English translation of NCT06743464 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a medication called rifaximin, given before and after liver transplant surgery, can help prevent early failure of the transplanted liver. The study will divide patients into two groups: one group will receive rifaximin along with standard care, and the other group will receive standard care alone. Researchers hope this medication will reduce serious complications that can happen in the first few weeks after transplant.
After a liver transplant, the new organ sometimes doesn't function well in the early weeks, which can be dangerous. This trial is exploring whether this medication might protect the new liver and improve outcomes for transplant patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive the medication twice daily starting two weeks before your transplant surgery and continuing for one week after surgery, or you will receive standard care without the medication. Both groups will receive the same regular post-transplant care and monitoring that all transplant patients receive at the hospital. The study will track how well your new liver works in the weeks following your transplant.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
India
Sponsor
Institute of Liver and Biliary Sciences, India
Enrollment target
~100 participants
Started
December 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tapan Kumar Pradhan, MS
Institute of Liver and Biliary Sciences, India
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.